Intermittent hypoxia sensitizes control centers in the brain, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.
Intermittent hypoxia sensitizes control centers in the brain, the result being exaggerated responses to even a minor change in breathing, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.
Transcript
How do the physiologies for obstructive and central sleep apnea overlap?
They overlap quite a bit, because each time there is a lack of the respiratory generator rhythm, which drives a breath, there is a pause in breathing because of a central apnea. So with each breath, it's not really that the diaphragm contracts and opens up the lung, the area has to be opened up also. So again, if there is no impulse to breathe, there is a tendency for the airway to narrow. A central sleep apnea can actually lead to airway collapse and obstruction. So that's one simplistic explanation.
The other thing is that in obstructive sleep apnea, we have a phenomenon called intermittent hypoxia, because oxygen levels keep fluctuating each time [the airway closes, reopens] when the patient wakes up, and then [closes] again as they drift into deep sleep. So this fluctuating oxygen levels sensitizes the control centers in the carotid body in the brain. And that can lead to something called an exaggerated response to any minor change in breathing, which may also cause some instability of breathing. Any instability of breathing at night, indeed, the more central apneas. So obstructive sleep apnea can lead to more central apneas, and central apneas lead to obstructive sleep apnea.
Again, practitioners need to understand what is driving what and what are the factors which [are] driving central sleep apnea in the [patients].
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More